Weak points in clinical trials for aesthetic dermatology- How to | 2220
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

Weak points in clinical trials for aesthetic dermatology- How to improve?

4th International Conference on Clinical & Experimental Dermatology

April 14-16, 2014 Hilton San Antonio Airport, TX, USA

Igor Rudenko

Accepted Abstracts: J Clin Exp Dermatol Res

Abstract :

Current situation in Aesthetic Dermatology needs more evidence-based data for proving safety of drug, devises and techniques. Unfortunately not all clinical trials are based on the principles of GCP and some of them contain bias. Clinical data that received in such trials cannot be use for building science and serves only as clinical experience with lowest rate of EBM. It were analyzed some clinical trials within aesthetic dermatology with revealing weak points and methods of its correction were proposed. Some clinical designs are demonstrated. We can organize clinical trials with sufficient evidence rate only with full understanding principles of GCP and methodology of bias avoiding.

Biography :

Igor Rudenko is an international speaker within Aesthetic and Dermatology fields: EMAA2012 (Paris), InterSharm2012 (Moscow), EAAD2012 (Moscow), DASIL2012 (Malta), IMCAS2013 - Paris, AWMC2013 - Monaco, NPI -ACCME cource - Charleston, SC (2013), Vegas Cosmetic Surgery2013 (Las-Vegas). He is leading provider of teaching and training courses regarding such techniques as Toxins injections, Fillers, Mezotherapy, PRP, Thread lift. Igor Rudenko has managed a number of clinical trials within oncology, cardiology, dermatology and respiratory areas. He took part into protocol development and finalization, safety managing, regulatory affair. Igor Rudenko is an active member of aesthetic dermatological professional community through memberships and leadership roles.